| Entry |
|
|---|
| Name |
Loxapine succinate (USP);
Loxitane (TN) |
|---|
| Product |
|
|---|
| Generic |
LOXAPINE (A-S Medication Solutions), LOXAPINE (Actavis Pharma), LOXAPINE (Burel Pharmaceuticals), LOXAPINE (Elite Laboratories), LOXAPINE (Lannett Company), LOXAPINE (REMEDYREPACK), LOXAPINE (REMEDYREPACK), LOXAPINE (REMEDYREPACK), LOXAPINE (REMEDYREPACK), LOXAPINE (REMEDYREPACK), LOXAPINE (REMEDYREPACK) |
|---|
| Formula |
C18H18ClN3O. C4H6O4
|
|---|
| Exact mass |
445.1404
|
|---|
| Mol weight |
445.8961
|
|---|
| Structure |
|
|---|
| Class |
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG01644 CYP2D6 substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Product (DG00897): | D02340<US> D00794<US> |
|
|---|
| Efficacy |
Minor tranquilizer, Dopamine D2 receptor antagonist, Serotonin receptor antagonist |
|---|
| Disease |
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
Enzyme: CYP1A2 [HSA: 1544], CYP3A4 [HSA: 1576], CYP2D6 [HSA: 1565]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05A ANTIPSYCHOTICS
N05AH Diazepines, oxazepines, thiazepines and oxepines
N05AH01 Loxapine
D00794 Loxapine succinate (USP) <US>
USP drug classification [BR:br08302]
Antipsychotics
1st Generation/Typical
Loxapine
D00794 Loxapine succinate (USP)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
DG00897 Loxapine
D00794 Loxapine succinate
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG00897 Loxapine
D00794 Loxapine succinate
DG01644 CYP2D6 substrate
DG00897 Loxapine
D00794 Loxapine succinate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00897 Loxapine
D00794 Loxapine succinate
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD2
D00794 Loxapine succinate (USP) <US>
Serotonin
HTR2A
D00794 Loxapine succinate (USP) <US>
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00794
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
DG00897 Loxapine
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG00897 Loxapine
DG01644 CYP2D6 substrate
DG00897 Loxapine
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00897 Loxapine
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 31
1 C6a C 38.6351 -18.6142
2 C1b C 37.4213 -19.3202
3 O6a O 39.8548 -19.3202
4 O6a O 38.6351 -17.2194
5 C1b C 36.2133 -18.6200
6 C6a C 35.0053 -19.3260
7 O6a O 33.7914 -18.6259
8 O6a O 35.0053 -20.7208
9 C2y C 28.7700 -17.5000
10 C8y C 27.9300 -16.3800
11 C8y C 28.2800 -15.0500
12 O2x O 29.5400 -14.4900
13 N2x N 30.1700 -17.5000
14 C8y C 30.8000 -15.1200
15 C8y C 31.0800 -16.4500
16 C8x C 27.2300 -14.0700
17 C8x C 25.9000 -14.4900
18 C8y C 25.5500 -15.8200
19 C8x C 26.6000 -16.8000
20 C8x C 32.4100 -16.8700
21 C8x C 33.4600 -15.9600
22 C8x C 33.1800 -14.5600
23 C8x C 31.8500 -14.1400
24 X Cl 24.2200 -16.2400
25 N1y N 28.1400 -18.7600
26 C1x C 26.7400 -18.7600
27 C1x C 26.0400 -19.9500
28 N1y N 26.7400 -21.2100
29 C1x C 28.1400 -21.2100
30 C1x C 28.8400 -19.9500
31 C1a C 26.0400 -22.4000
BOND 33
1 1 2 1
2 1 3 1
3 1 4 2
4 2 5 1
5 5 6 1
6 6 7 1
7 6 8 2
8 11 12 1
9 9 13 2
10 12 14 1
11 10 11 1
12 13 15 1
13 9 10 1
14 14 15 1
15 11 16 2
16 16 17 1
17 17 18 2
18 18 19 1
19 10 19 2
20 15 20 2
21 20 21 1
22 21 22 2
23 22 23 1
24 14 23 2
25 18 24 1
26 9 25 1
27 25 26 1
28 26 27 1
29 27 28 1
30 28 29 1
31 29 30 1
32 25 30 1
33 28 31 1
|
|---|
